Literature DB >> 22985882

Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages.

Jérôme Larché1, Flavie Pouillot, Christiane Essoh, Balázs Libisch, Monica Straut, Je Chul Lee, Charles Soler, Richard Lamarca, Elodie Gleize, Jérôme Gabard, Gilles Vergnaud, Christine Pourcel.   

Abstract

The objective of this study was to determine the genetic diversity of multidrug-resistant (MDR) Pseudomonas aeruginosa strains isolated over a period of 12 months in two French hospitals and to test their susceptibility to bacteriophages. A total of 47 MDR isolates recovered from hospitalized patients were genotyped using multiple-locus variable number of tandem repeats analysis. The genotypes were distributed into five clones (including 19, 5, 5, 3, and 3 isolates, respectively) and 12 singletons. Comparison to 77 MDR strains from three other countries, and MLST analysis of selected isolates showed the predominance of international MDR clones. The larger clone, CC235, contained 59 isolates displaying different antibiotic resistance mechanisms, including the presence of the GES1, VIM-2, VIM-4, and IMP-1 β-lactamases. Three newly isolated P. aeruginosa bacteriophages were found to lyse 42 of the 44 analyzed strains, distributed into the different clonal complexes. This pilot study suggests that systematic genotyping of P. aeruginosa MDR strains could improve our epidemiological understanding of transmission at both the local (hospital) and the national level and that phage therapy could be an alternative or a complementary treatment to antibiotics for treating MDR-infected patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22985882      PMCID: PMC3497159          DOI: 10.1128/AAC.01233-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  A new highly discriminatory multiplex capillary-based MLVA assay as a tool for the epidemiological survey of Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  D Sobral; P Mariani-Kurkdjian; E Bingen; H Vu-Thien; K Hormigos; B Lebeau; F Loisy-Hamon; A Munck; G Vergnaud; C Pourcel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-11       Impact factor: 3.267

2.  The phage therapy paradigm: prêt-à-porter or sur-mesure?

Authors:  Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Maia Merabishvili; Nina Chanishvili; Mario Vaneechoutte; Martin Zizi; Geert Laire; Rob Lavigne; Isabelle Huys; Guy Van den Mooter; Angus Buckling; Laurent Debarbieux; Flavie Pouillot; Joana Azeredo; Elisabeth Kutter; Alain Dublanchet; Andrzej Górski; Revaz Adamia
Journal:  Pharm Res       Date:  2010-11-10       Impact factor: 4.200

3.  Observations on bacteriophage typing of Pseudomonas aeruginosa.

Authors:  B POSTIC; M FINLAND
Journal:  J Clin Invest       Date:  1961-11       Impact factor: 14.808

4.  Virulence and antimicrobial resistance determinants of human pathogenic and commensal strains of Pseudomonas aeruginosa.

Authors:  Annamária Szmolka; B Libisch; Judit Pászti; M Füzi; L Emody; B Nagy
Journal:  Acta Microbiol Immunol Hung       Date:  2009-12       Impact factor: 2.048

5.  Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.

Authors:  Esther Viedma; Carlos Juan; Joshi Acosta; Laura Zamorano; Joaquín R Otero; Francisca Sanz; Fernando Chaves; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 6.  Phage therapy in clinical practice: treatment of human infections.

Authors:  Elizabeth Kutter; Daniel De Vos; Guram Gvasalia; Zemphira Alavidze; Lasha Gogokhia; Sarah Kuhl; Stephen T Abedon
Journal:  Curr Pharm Biotechnol       Date:  2010-01       Impact factor: 2.837

7.  Molecular typing indicates an important role for two international clonal complexes in dissemination of VIM-producing Pseudomonas aeruginosa clinical isolates in Hungary.

Authors:  Balázs Libisch; Joseph Watine; Boglárka Balogh; Mária Gacs; Mónika Muzslay; Gitta Szabó; Miklós Füzi
Journal:  Res Microbiol       Date:  2008-01-11       Impact factor: 3.992

8.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

Authors:  Rebecca R Roberts; Bala Hota; Ibrar Ahmad; R Douglas Scott; Susan D Foster; Fauzia Abbasi; Shari Schabowski; Linda M Kampe; Ginevra G Ciavarella; Mark Supino; Jeremy Naples; Ralph Cordell; Stuart B Levy; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

9.  Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients.

Authors:  Antonella Agodi; Martina Barchitta; Rosalba Cipresso; Loredana Giaquinta; Maria Antonietta Romeo; Carmelo Denaro
Journal:  Intensive Care Med       Date:  2007-05-15       Impact factor: 17.440

10.  Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth.

Authors:  André M Comeau; Françoise Tétart; Sabrina N Trojet; Marie-Françoise Prère; H M Krisch
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

View more
  11 in total

1.  Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Pharm Res       Date:  2016-02-29       Impact factor: 4.200

2.  Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Elizabeth A Carter; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2017-02-03       Impact factor: 5.875

3.  Impact of FiuA Outer Membrane Receptor Polymorphism on the Resistance of Pseudomonas aeruginosa toward Peptidoglycan Lipid II-Targeting PaeM Pyocins.

Authors:  Libera Latino; Delphine Patin; Dimitri Chérier; Thierry Touzé; Christine Pourcel; Hélène Barreteau; Dominique Mengin-Lecreulx
Journal:  J Bacteriol       Date:  2019-06-10       Impact factor: 3.490

4.  Dissemination of high-risk clones of extensively drug-resistant Pseudomonas aeruginosa in colombia.

Authors:  Adriana Correa; Rosa Del Campo; Marcela Perenguez; Victor M Blanco; Mercedes Rodríguez-Baños; Federico Perez; Juan J Maya; Laura Rojas; Rafael Cantón; Cesar A Arias; Maria V Villegas
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

Review 5.  Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis.

Authors:  María José Martínez-Gallardo; Claudia Villicaña; Martha Yocupicio-Monroy; Sofía Lizeth Alcaraz-Estrada; Josefina León-Félix
Journal:  Folia Microbiol (Praha)       Date:  2022-08-05       Impact factor: 2.629

Review 6.  Nanobiosystems for Antimicrobial Drug-Resistant Infections.

Authors:  Foteini Gkartziou; Nikolaos Giormezis; Iris Spiliopoulou; Sophia G Antimisiaris
Journal:  Nanomaterials (Basel)       Date:  2021-04-22       Impact factor: 5.076

Review 7.  Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.

Authors:  Martina Rossitto; Ersilia V Fiscarelli; Paola Rosati
Journal:  Front Microbiol       Date:  2018-05-04       Impact factor: 5.640

8.  The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.

Authors:  Christiane Essoh; Yann Blouin; Guillaume Loukou; Arsher Cablanmian; Serge Lathro; Elizabeth Kutter; Hoang Vu Thien; Gilles Vergnaud; Christine Pourcel
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

9.  Carbapenemase-producing Pseudomonas aeruginosa from central Greece: molecular epidemiology and genetic analysis of class I integrons.

Authors:  Apostolos Liakopoulos; Angeliki Mavroidi; Efstathios A Katsifas; Alexandros Theodosiou; Amalia D Karagouni; Vivi Miriagou; Efthymia Petinaki
Journal:  BMC Infect Dis       Date:  2013-10-29       Impact factor: 3.090

10.  Four genotyping schemes for phylogenetic analysis of Pseudomonas aeruginosa: comparison of their congruence with multi-locus sequence typing.

Authors:  Makaoui Maâtallah; Amina Bakhrouf; Muhammed Asif Habeeb; Agata Turlej-Rogacka; Aina Iversen; Christine Pourcel; Olfa Sioud; Christian G Giske
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.